Effects of 23-epi-26-deoxyactein on adipogenesis in 3T3-L1 preadipocytes and diet-induced obesity in C57BL/6 mice

Jingjing Yuan,Qiangqiang Shi,Juan Chen,Jing Lu,Lu Wang,Minghua Qiu,Jian Liu

DOI: https://doi.org/10.1016/j.phymed.2020.153264

IF: 6.656

2020-09-01

Phytomedicine

Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Background</h3><p>: The ethanolic extract of <em>Actaea racemosa</em> L. (<em>Cimicifuga racemosa</em> (L.) Nutt.) has recently been reported to ameliorate obesity-related insulin resistance, hyperlipidemia, and fatty liver in rodents. However, it remains unclear which <em>A. racemosa</em> components are responsible for these beneficial effects.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Purpose</h3><p>: We aimed to examine the anti-obesity potential of 23-epi-26-deoxyactein (DA), which is contained in the ethanolic extracts of <em>A. racemosa</em>.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Study design and methods</h3><p>: To evaluate the effects of DA on adipogenesis in 3T3-L1 preadipocytes and diet-induced obesity in C57BL/6 mice, <em>in vitro</em> and <em>in vivo</em> tests were performed. For <em>in vitro</em> assessment, we used Oil red O staining that showed lipid accumulation in differentiated 3T3-L1 cells. For <em>in vivo</em> tests, male 5-week-old C57BL/6 mice were fed with low-fat diet (LFD), high-fat diet (HFD), HFD with 10 mg/kg/d luteolin (LU; positive control drug), HFD with 1 mg/kg/d DA, and HFD with 5 mg/kg/d DA for 12 weeks, respectively. Glucose and insulin tolerance tests were performed at week 17. The lipid deposition of adipose tissue and liver was visualized by hematoxylin and eosin staining. Real-time PCR showed mRNA levels of genes involved in adipogenesis, lipogenesis, and lipolysis. AMPK signaling and SIRT1-FOXO1 pathway were assessed by real-time PCR and western blot.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>: 10 μM DA and 20 μM LU treatments inhibited 3T3-L1 adipogenesis through down-regulating the expression of <em>C/ebpα, C/ebpβ</em>, and <em>Pparγ</em>, which are the critical adipogenic transcription factors. The <em>in vivo</em> results showed that 5 mg/kg/d DA and 10 mg/kg/d LU significantly lowered body weight gain, fat mass, and liver weight in HFD-fed mice. Meanwhile, DA and LU also reduced insulin resistance and serum lipoprotein levels in HFD-fed mice. Mechanistic studies showed that DA and LU promoted adipocyte lipolysis in mice through activating the AMPK signaling and SIRT1-FOXO1 pathway.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusion</h3><p>: The <em>in vitro</em> results indicate that 10 μM DA suppresses adipogenesis in 3T3-L1 preadipocytes. The <em>in vivo</em> treatment with 5 mg/kg/d DA ameliorates diet-induced obesity in mice, suggesting that DA is a promising natural compound for the treatment of obesity and related metabolic diseases.</p>

pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences

What problem does this paper attempt to address?

The paper aims to investigate the effects of 23-epi-26-deoxyactein (DA) on the differentiation of 3T3-L1 preadipocytes and diet-induced obesity in mice. Specifically, the research objectives include the following aspects:

1. **Inhibition of Adipogenesis**: To explore the inhibitory effect of DA on the differentiation process of 3T3-L1 preadipocytes in vitro.
2. **Improvement of Obesity Symptoms**: To evaluate whether DA can alleviate high-fat diet-induced obesity in mice in vivo, and to analyze its effects on weight gain, fat accumulation, and liver fat deposition.
3. **Impact on Metabolic-Related Diseases**: To investigate the mechanisms by which DA affects obesity-related metabolic disorders such as insulin resistance, fatty liver, and dyslipidemia.
4. **Exploration of Molecular Mechanisms**: To explore the specific molecular mechanisms by which DA improves obesity and its complications by detecting the expression levels of genes related to adipogenesis and lipolysis.

In summary, this paper attempts to validate the efficacy and potential mechanisms of DA as a natural compound in the treatment of obesity and related metabolic diseases through a series of in vivo and in vitro experiments.